Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 32
Posts 27,328
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Big Homes Can Complicate Retirement
Once you've paid for your house, how much will it cost you?
China Mobile's Need for Speed -- Barron's Asia
Intel Projects More Growth in 2015 -- Update
Zoetis Unveils $500 Million Stock Buyback Plan -- Update
Technip Bids for CGG -- 2nd Update
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
Wireless Carriers Bid Up US Airwaves To Record
Two Top-Producing Advisers Leave Merrill Lynch--Street Moves
Chinese Premier Plays Down Qualcomm's Woes
Activision Blizzard to Get $275 Million in Settlement
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 68862 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist